Quantcast
Last updated on April 24, 2014 at 10:25 EDT

Latest B-cell chronic lymphocytic leukemia Stories

2013-12-07 08:20:47

-- Data at ASH show increased scientific understanding of CTL019 and its potential role in the treatment of certain types of lymphocytic leukemia(1,2,3,4) EAST HANOVER, N.J., Dec. 7, 2013 /PRNewswire/ -- Novartis is highlighting new research from members of the faculty at the University of Pennsylvania's Perelman School of Medicine (Penn) on the investigational chimeric antigen receptor (CAR) therapy, CTL019. Several studies being presented at the American Society of Hematology (ASH) annual...

2013-12-07 08:20:41

Researchers Unveil First Results in Adult ALL Patients: All Five Patients Had Complete Response to Therapy NEW ORLEANS, Dec. 7, 2013 /PRNewswire/ -- Three and a half years after beginning a clinical trial which demonstrated the first successful and sustained use of genetically engineered T cells to fight leukemia, a research team from the Perelman School of Medicine at the University of Pennsylvania and the Children's Hospital of Philadelphia will today announce the latest results of studies...

2013-12-07 08:20:35

--Researchers at The Children's Hospital of Philadelphia and the University of Pennsylvania Harness Engineered T Cells to Eliminate Tumors in Blood-- NEW ORLEANS, Dec. 7, 2013 /PRNewswire/ -- Nearly 90 percent of children and adults with a highly aggressive form of acute lymphoblastic leukemia (ALL) showed no evidence of cancer after receiving a novel, personalized cell therapy that reprograms a patient's immune system. In pilot studies of bioengineered T cells that attack leukemia,...

2013-12-06 23:23:51

“Dual Inhibition Of Mcl-1 By The Combination Of Carfilzomib and TG02 In Multiple Myeloma” and “Leukemia Stem/Progenitor Cells From AML Patients Treated With The Multi-Kinase Inhibitor TG02 Demonstrate Increased Proliferation and Are Sensitized To Chemotherapeutic Agents” San Diego (PRWEB) December 06, 2013 Tragara Pharmaceuticals, Inc. today announced that two posters on TG02, the Company's unique oral multi-kinase inhibitor, will be presented at the American Society of...

2013-12-05 12:29:45

WHITE PLAINS, N.Y., Dec. 5, 2013 /PRNewswire/ -- Many researchers funded by The Leukemia & Lymphoma Society (LLS) will be among those presenting exciting new directions in blood cancer research at the 55th American Society of Hematology (ASH) Annual Meeting and Exposition in New Orleans in early December. The meeting takes place from December 7-10 at the Ernest N. Morial Convention Center. Advances in immune-stimulating therapies, moleculary-targeted drug therapies, including...

2013-11-26 08:27:10

CAMBRIDGE, England, November 26, 2013 /PRNewswire/ -- Cytocell Ltd. announced the availability of a new range of in vitro diagnostic tests to aid in detecting patients with Chronic Lymphocytic Leukaemia (CLL), a cancer of the lymphocytes. (Logo: http://photos.prnewswire.com/prnh/20120906/559436 ) The new range of Cytocell CLL FISH probes includes the new CLL PROFILER Kit comprising of the P53/ATM Probe Combination and a newly developed D13S319/13qter/12cen...

2013-11-19 08:28:41

Findings Highlight Company's Growing Hematologic Area of Focus, Including Ibrutinib, Siltuximab and Daratumumab RARITAN, N.J., Nov. 19, 2013 /PRNewswire/ -- Janssen Research & Development, LLC (Janssen) announced that data related to three Janssen compounds have been selected for presentation at the 55(th) American Society of Hematology (ASH) Annual Meeting in New Orleans, LA. Nine pieces of company-sponsored research will be presented out of a total of nearly 50 abstracts involving...

2013-11-13 16:26:31

Ibrutinib becomes second drug with 'breakthrough therapy designation' approved by FDA WHITE PLAINS, N.Y., Nov. 13, 2013 /PRNewswire/ -- Today's U.S. Food and Drug Administration (FDA) approval of ibrutinib to treat patients with mantle cell lymphoma (MCL) is a significant advance for patients with this blood cancer. It was approved as a single agent for treatment of patients with MCL who have received at least one prior therapy. Ibrutinib is the second drug with "breakthrough...

2013-11-13 12:27:59

Single-agent oral therapy is one of the first medications to be approved via the U.S. Food and Drug Administration's Breakthrough Therapy Designation Pathway HORSHAM, Pa., Nov. 13, 2013 /PRNewswire/ -- Janssen Biotech, Inc. ["Janssen"] today announced the U.S. Food and Drug Administration (FDA) has approved IMBRUVICA(TM) (ibrutinib) capsules for the treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.(1) This indication is based on...

2013-11-07 16:32:03

SUNNYVALE, Calif., Nov. 7, 2013 /PRNewswire/ -- Pharmacyclics, Inc. (the "Company") (Nasdaq: PCYC) today reported financial results and recent developments for the quarter ended September 30, 2013. Financial Results for the Three and Nine Months Ended September 30, 2013 Revenue for the quarter ended September 30, 2013 was $79.1 million compared to $54.7 million for the quarter ended June 30, 2013 and $102.7 million for the quarter ended September 30, 2012. Included in revenue for the three...